Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245

Recent advances in vascular biology: Selected highlights from IVBM 2008

Issue: 2009: 101/6 (June) pp. 796-1180
Pages: 1147-1155

Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer

Katja Haubold1#; Michael Rink2#; Brigitte Spath 1; Martin Friedrich 2; Felix Kyoung-Hwan Chun 2; Guy Marx 3; Ali Amirkhosravi 4; John L. Francis 4; Carsten Bokemeyer 1; Barbara Eifrig 1; Florian Langer1
1 Onkologisches Zentrum, II. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg, Germany; 2 Klinik und Poliklinik für Urologie, Universitätsklinikum Eppendorf, Hamburg, Germany; 3 Institut für Klinische Chemie, Universitätsklinikum Eppendorf, Hamburg, Germany; 4 Center for Thrombosis Research, Florida Hospital, Orlando, Florida, USA


cancer, microparticles, tissue factor / factor VIIa


Tissue factor (TF) plays a critical role in tumour growth and metastasis, and its enhanced release into plasma in association with cellular microparticles (MPs) has recently been associated with pathological cancer progression. We have previously demonstrated significantly elevated levels of plasma TF antigen as well as systemic coagulation and platelet activation in patients with localised prostate cancer. In this prospective study, we used a highly sensitive one-stage clotting assay to measure preoperative TF-specific procoagulant activity (PCA) of plasma MPs in 68 consecutive patients with early-stage prostate cancer to further explore the relevance of circulating TF in this tumour entity. Automated calibrated thrombography was used to monitor thrombin generation in cell-free plasma samples in the absence of exogenous TF or phospholipids. Compared to healthy male controls (n=20), patients had significantly increased levels of both D-dimer and TF-specific PCA of plasma MPs (p<0.001). Furthermore, MP-associated TF PCA was higher in patients with (n=29) than in those without (n=39) laboratory evidence of an acute-phase reaction (p=0.004) and decreased to normal levels within one week after radical prostatectomy. Overall, we found a significant correlation between TF-specific PCA of plasma MPs and plasma D-dimer (p=0.002), suggesting that plasma MPs contributed to in-vivo coagulation activation in a TF-dependent manner. Thrombin generation in plasma was also significantly increased in patients compared to controls (p<0.01). Collectively, our findings suggest that TF-specific PCA of plasma MPs contributes to intravascular coagulation activation in patients with early-stage prostate cancer and may represent a potential link between hypercoagulability, inflammation, and disease progression.

You may also be interested in...

Florian Langer 1, Felix Kyoung-Hwan Chun 2, Ali Amirkhosravi 3, Martin Friedrich 2, Sven Leuenroth 4, Barbara Eifrig 1, Carsten Bokemeyer 1, John L. Francis3

Thromb Haemost 2007 97 3: 464-470

Gregor Hron 1, Marietta Kollars 1, Heinz Weber 1, Verena Sagaster 1, Peter Quehenberger 2, Sabine Eichinger 1, Paul A. Kyrle 1, Ansgar Weltermann1

Thromb Haemost 2007 97 1: 119-123


C. Dicke (1), F. Langer (1)

Hämostaseologie 2015 35 1: 52-59